519 related articles for article (PubMed ID: 25956579)
21. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
[TBL] [Abstract][Full Text] [Related]
23. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
25. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
26. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
[TBL] [Abstract][Full Text] [Related]
27. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
De Camargo Cancela M; Comber H; Sharp L
Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
[TBL] [Abstract][Full Text] [Related]
28. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
29. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer.
Wong SM; Freedman RA; Sagara Y; Aydogan F; Barry WT; Golshan M
Ann Surg; 2017 Mar; 265(3):581-589. PubMed ID: 28169929
[TBL] [Abstract][Full Text] [Related]
30. HER2-Overexpressing Ductal Carcinoma
O'Keefe TJ; Blair SL; Hosseini A; Harismendy O; Wallace AM
Cancer Prev Res (Phila); 2020 Sep; 13(9):761-772. PubMed ID: 32493703
[TBL] [Abstract][Full Text] [Related]
31. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
34. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
36. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
37. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
38. Impact of Primary Tumor Surgery in Stage IV Male Breast Cancer.
Muzaffar M; Kachare S; Vohra N
Clin Breast Cancer; 2017 Jun; 17(3):e143-e149. PubMed ID: 27998656
[TBL] [Abstract][Full Text] [Related]
39. Breast-conserving Surgery Rates in Breast Cancer Patients With Different Molecular Subtypes: An Observational Study Based on Surveillance, Epidemiology, and End Results (SEER) Database.
Chen K; Li S; Li Q; Zhu L; Liu Y; Song E; Su F
Medicine (Baltimore); 2016 Feb; 95(8):e2593. PubMed ID: 26937898
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]